14 Results for "

DOPE-PEG2000-VHPKQHRGGSKGC

" in MedChemExpress (MCE) Product Catalog:
Products (14)

14 Results for "DOPE-PEG2000-VHPKQHRGGSKGC" in MCE Product Catalog:

Cat. No.: HY-187412A
Research Areas:  

Cancer

DOPE-PEG2000-VHPKQHRGGSKGC is an amphiphilic lipid-PEG-peptide conjugate consisting of DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine), PEG2000, and the VHPKQHRGGSKGC peptide, a tumor-targeting peptide containing a terminal cysteine for conjugation. DOPE-PEG2000-VHPKQHRGGSKGC is used for tumor-targeted drug delivery via liposome and nanoparticle surface modification.
loading...
    loading...
Cat. No.: HY-P10392AF
Target:  

Wnt β-catenin

Research Areas:  

Cancer

fStAx-35R TFA is the hydrocarbon-stapled peptide. fStAx-35R TFA inhibits Wnt/β-catenin signaling pathway by disrupting the β-catenin-TCF interaction. fStAx-35R TFA can be used in cancer research .
loading...
    loading...
Cat. No.: HY-P10896
CAS No.: 1446005-10-2
Target:  

Bombesin Receptor

Research Areas:  

Cancer

NOTA-P2-RM26 is an antagonist of Bombesin (HY-P0195) analogs, and the gastrin-releasing peptide receptor (GRPR/BB2) is a molecular target for prostate cancer visualization. NOTA-P2-RM26 is labeled with 111In and 68Ga for prostate cancer imaging studies using PET and SPECT/CT .
loading...
    loading...
Cat. No.: HY-P11088
CAS No.: 1311293-04-5
VCAM1 binding peptide is a VCAM1 binder with internalization activity. VCAM1 binding peptide can be labeled with 5-FAM. VCAM1 binding peptide serves as a component of biosensing systems for visualizing in vitro VCAM1 endocytic pathways. VCAM1 binding peptide forms the research and development basis for MacroP and NAMP, PET radiotracers targeting VCAM1. VCAM1 binding peptide is applicable to studies related to atherosclerosis .
loading...
    loading...
Cat. No.: HY-169232
Target:  

PROTACs PD-1/PD-L1

Research Areas:  

Cancer

PCC16 chloride is a dual PROTAC degrader targeting DHHC3 and PD-L1, with a DC50 of 0.103 μM for PD-L1 degradation. PCC16 chloride induces DHHC3 degradation via the ubiquitin-proteasome pathway by recruiting the CRBN E3 ubiquitin ligase (E3 ubiquitin ligase). By targeting DHHC3-which is essential for PD-L1 palmitoylation and membrane stability-PCC16 chloride reduces PD-L1 levels, decreases PD-L1 membrane retention time, and impairs its immunosuppressive function. PCC16 chloride enhances anti-tumor immunity by disrupting PD-L1-mediated immunosuppression. PCC16 chloride can be used in the research of immune checkpoint blockade-resistant cancers .
loading...
    loading...
Cat. No.: HY-P11088A
VCAM1 binding peptide acetate is a VCAM1 binder with internalization activity. VCAM1 binding peptide acetate can be labeled with 5-FAM. VCAM1 binding peptide acetate serves as a component of biosensing systems for visualizing in vitro VCAM1 endocytic pathways. VCAM1 binding peptide acetate forms the research and development basis for MacroP and NAMP, PET radiotracers targeting VCAM1. VCAM1 binding peptide acetate is applicable to studies related to atherosclerosis .
loading...
    loading...
Cat. No.: HY-P11887
CAS No.: 1174559-81-9
VHPKQHR is a peptide-based delivery enhancer that binds to VCAM-1. VHPKQHR enables intracellular internalization of relevant nanomaterials and facilitates the targeted delivery of miRNA inhibitors to inflamed endothelial cells and endothelial cells activated by disturbed flow. When conjugated with magnetic mesoporous silica nanoparticles, VHPKQHR achieves targeted accumulation at atherosclerotic plaque sites. When displayed on the surface of polyelectrolyte complex micelles, VHPKQHR enhances the relevant effects of anti-miR-92a in Apoe -/- mice. When conjugated with ultrasmall superparamagnetic iron oxide nanoparticles, VHPKQHR forms a contrast agent for T1-weighted magnetic resonance imaging. VHPKQHR can be used in research related to atherosclerosis, stenosis and rheumatoid arthritis .
loading...
    loading...
Cat. No.: HY-P11088F
VCAM1 binding peptide, FITC labeled acetate is a FITC-labeled VCAM1 binding peptide acetate (HY-P11088A). VCAM1 binding peptide acetate is a VCAM1 binder with internalization activity. VCAM1 binding peptide acetate serves as a component of biosensing systems for visualizing in vitro VCAM1 endocytic pathways. VCAM1 binding peptide acetate forms the research and development basis for MacroP and NAMP, PET radiotracers targeting VCAM1. VCAM1 binding peptide acetate is applicable to studies related to atherosclerosis .
loading...
    loading...
Cat. No.: HY-P12133
CAS No.: 3080063-21-1
Target:  

GLP Receptor

Research Areas:  

Metabolic Disease

Tapimtrutide is a gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. Tapimtrutide can be used for the research of diabetes .
loading...
    loading...
Cat. No.: HY-P11625
Target:  

RXFP Receptor

Research Areas:  

Cardiovascular Disease

R9-13 is a fatty acid-conjugated relaxin and an agonist of LGR7 (RXFP1). R9-13 induces sustained pubic symphysis elongation in estrogen-pretreated mice. R9-13 exhibits long-acting pharmacokinetic profiles in rodents, with in vivo activity lasting up to one week after administration. R9-13 can be used in studies related to acute heart failure .
loading...
    loading...
Cat. No.: HY-P11830
Target:  

Amylin Receptor

Research Areas:  

Metabolic Disease

UDA-6 is a potent calcitonin and amylin receptor agonist (DACRA). UDA-6 induces weight loss, improves metabolic and hepatic parameters, and stabilizes active receptor states in obesity rats. UDA-6 can be used for the research of obesity .
loading...
    loading...
Cat. No.: HY-P11596
CAS No.: 3107808-75-0
Target:  

Integrin

Research Areas:  

Cancer

NOTA-Asp2-αvβ6L is an integrin αvβ6 binder with selective accumulation in αvβ6-positive pancreatic cancer cells and tumors. NOTA-Asp2-αvβ6L can be used as a PET/CT tracer for imaging pancreatic ductal adenocarcinoma (PDAC) .
loading...
    loading...
Cat. No.: HY-P11846
Target:  

ADAMTS

Research Areas:  

Cardiovascular Disease

ADA2 is an ADAMTS4-binding peptide and imaging agent with a human ADAMTS4 Ka of 5.3 nM and reduced renal uptake compared to related tracers. ADA2 accumulates in dilated aortic regions in aortic aneurysm mouse models. ADA2 exhibits an in vivo safety profile. ADA2 can be used for the research of aortic aneurysm .
loading...
    loading...
Cat. No.: HY-P3252AS
Pegcetacoplan- 13C3, 15N TFA is the 13C- and 15N-labeled Pegcetacoplan TFA. Pegcetacoplan is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).
loading...
    loading...
  • 1